Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector

Phase 3positiverisvutatug rezetecanPositive

AI Analysis

Summary

Hansoh announced Phase 3 success for its GSK-partnered ADC risvutatug rezetecan (Ris-Rez) in small cell lung cancer, meeting the primary endpoint. Separately, the FDA approved Sanofi's on-body injector, with additional news from Huntington's disease, Fate Therapeutics, and Bausch + Lomb programs.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Met primary endpoint

Importance:7/10

Sentiment:

0.70

Phase 3ADCSCLCFDA approvalon-body injectorHuntington's

Related Companies

$HNPHY $GSK $SNY $FATE

Read the original article

Published by Endpoints News on July 10, 2026 2:35 PM

Read Original